Lpath Incorporated

• Home
• About Lpath
  • Brief Overview
  • Company Summary
  • Pipeline
  • Our Novel Approach
  • Patent Portfolio
  • Pioneers of the Category
• The Lpath Team
  • Executive Team
  • Board of Directors
  • Advisory Boards
    • Clinical
    • Ocular
    • Scientific
• The Science: An Overview
  • Technical Overview
    • S1P Target
    • LPA Target
  • Science of Cancer
  • Angiogenesis Tutorial
  • Publications/Presentations/ Grants
• Investor Center
  • Investor Overview
  • Stock Information
  • News Releases
  • Calendar of Events
  • SEC Filings
  • Investor FAQ
  • Request Information
  • Email Alerts
• Legal, Important Notices
• Contact Us

Brief Overview

Updated: August 12, 2007

Lpath, Inc., headquartered in San Diego, California, is the category leader in lipidomics-based therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases.

Lpath's lead product candidate, ASONEP™ (the systemic formulation of Sphingomab™), is a monoclonal antibody against a validated cancer target, sphingosine-1-phosphate (S1P). ASONEP™ is potently anti-angiogenic, yet it has other mechanisms of action that may prove advantageous in the clinical setting. As such, Lpath believes ASONEP™ may represent the next generation of anti-angiogenesis-based therapeutics. We anticipate filing an IND for ASONEP use against cancer in the fourth quarter of 2007.

Lpath's second product candidate, iSONEP™ (the ocular formulation of Sphingomab™), has demonstrated superior results in various preclinicial AMD models and first-in-class results in a preclinical model of ischemic retinopathy. In addition, the drug candidate has shown anti-fibrotic mechanisms that might provide comparative advantage in the AMD realm and is also suggestive of efficacy against glaucoma when surgery is required. We plan to file an IND for iSONEP™ use against AMD in the first quarter of 2008.

Lpath's third product candidate, Lpathomab™, is a monoclonal antibody against lysophosphatidic acid (LPA), a key bioactive lipid that has long been recognized as a significant promoter of cancer-cell growth and metastasis in a broad range of tumor types and a significant contributor to neuropathic pain. We have demonstrated a strong anti-angiogenic mechanism of action for Lpathomab™ and have shown encouraging results in several models of AMD and cancer.

Lpath's unique ability to generate antibodies against bioactive lipids is based on its proprietary ImmuneY2™ drug-discovery engine. The company is currently applying the ImmuneY2™ technology to other important lipid-signaling agents, thereby adding to our pipeline of novel antibody-based drug candidates.

Lpath has a broad and deep intellectual-property position in the lysolipid signaling area, with over 26 issued or pending patents in the U.S., with corresponding international applications. Most of these patents were developed in-house based on pioneering research by the Company's founder, Roger Sabbadini, Ph.D., on bioactive lipid signaling.